The goal of this study is to develop an effective, sensitive blood test that can detect early tumours in patients with known or suspected hereditary cancer syndromes (HCS). If this new blood test is accurate, it could be used to screen patients for cancer and allow for earlier cancer detection. The study will also use questionnaires and interviews to understand how patients feel about incorporating these tests into routine medical care, and the perceptions of the medical value of test results.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Collection of biospecimens from 1500 HSC carriers.
Timeframe: up to 4 years
Collection of clinical data from 1500 HSC carriers.
Timeframe: up to 4 years
Detection of early stage cancer in HCS patients using cfDNA.
Timeframe: up to 4 years
Evaluation of the clinical utility of a cfDNA test for HSC patients.
Timeframe: up to 4 years
Evaluation of the optimal implementation of cfDNA in clinical practice.
Timeframe: up to 4 years
Evaluation of cfDNA test implementation through cost-effectiveness analysis of cfDNA versus standard of care.
Timeframe: up to 4 years